ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Nebraska » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in Nebraska

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
STEVEN KRUEGER M.D.

Cardiovascular Disease

10,954

$685K

860
773 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 23%

$63
Average prescription price

Avg: $51

DOUGLAS WELSH M.D.

Cardiovascular Disease

10,311

$408K

732
664 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 23%

$40
Average prescription price

Avg: $51

MICHAEL DEHNING MD

Cardiovascular Disease

9,696

$494K

764
705 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 23%

$51
Average prescription price

Avg: $51

PETER DIONISOPOULOS MD

Cardiovascular Disease

9,277

$499K

875
767 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 23%

$54
Average prescription price

Avg: $51

WILLIAM VOSIK M.D.

Cardiovascular Disease

8,258

$392K

305
295 are 65+

5%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 23%

$47
Average prescription price

Avg: $51

RANDAL CASSLING MD

Cardiovascular Disease

8,231

$512K

568
530 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 23%

$62
Average prescription price

Avg: $51

MARWAN SALFITY MD

Cardiovascular Disease

8,057

$399K

566
512 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 23%

$50
Average prescription price

Avg: $51

DALE HANSEN M.D.

Cardiovascular Disease

7,786

$389K

782
712 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 23%

$50
Average prescription price

Avg: $51

MICHAEL PETERS MD

Cardiovascular Disease

7,690

$412K

576
531 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 23%

$54
Average prescription price

Avg: $51

PETER MCLEAY MD

Cardiovascular Disease

7,047

$362K

385
346 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 23%

$51
Average prescription price

Avg: $51

RICK HEIRIGS MD

Cardiovascular Disease

6,667

$299K

703
626 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 23%

$45
Average prescription price

Avg: $51

MUHAMMAD KHAN M.D.

Cardiovascular Disease

6,605

$332K

469
442 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 23%

$50
Average prescription price

Avg: $51

JACQUELINE CHANLATTE-GARCIA MD

Cardiovascular Disease

6,390

$528K

242
174 are 65+

16%
patients receiving schedule two controlled substances

Avg: 0%

9%
patients receiving schedule three controlled substances

Avg: 0%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 23%

$83
Average prescription price

Avg: $51

PRADIPTA CHAUDHURI MD

Cardiovascular Disease

6,354

$475K

630
559 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 23%

$75
Average prescription price

Avg: $51

KALIPRASAD AYALA MD

Cardiovascular Disease

6,212

$244K

715
651 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 23%

$39
Average prescription price

Avg: $51

OMAR NASS M.D.

Cardiovascular Disease

6,090

$237K

637
561 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 23%

$39
Average prescription price

Avg: $51

ANUJ JAIN MD

Cardiovascular Disease

5,863

$221K

737
657 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 23%

$38
Average prescription price

Avg: $51

RONALD PRITZA M.D.

Cardiovascular Disease

5,638

$324K

500
457 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

25%
prescriptions for brand name drugs

Avg: 23%

$57
Average prescription price

Avg: $51

STANISLAW SOJKA MD

Cardiovascular Disease

5,399

$271K

421
383 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 23%

$50
Average prescription price

Avg: $51

CHARLES OLSON MD

Cardiovascular Disease

5,363

$245K

477
449 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 23%

$46
Average prescription price

Avg: $51

SCOTT COATSWORTH M.D.

Cardiovascular Disease

5,218

$200K

560
506 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 23%

$38
Average prescription price

Avg: $51

MARK CHOUINARD MD

Cardiovascular Disease

4,538

$290K

356
316 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 23%

$64
Average prescription price

Avg: $51

KEITH MILLER M.D.

Cardiovascular Disease

4,472

$206K

497
444 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 23%

$46
Average prescription price

Avg: $51

SHIRLEY HUERTER M.D.

Cardiovascular Disease

4,349

$207K

398
365 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 23%

$48
Average prescription price

Avg: $51

CHRISTOPHER LAMBERT M.D.

Cardiovascular Disease

4,218

$233K

417
378 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 23%

$55
Average prescription price

Avg: $51

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank